查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421583

药物基因组学技术市场、份额、规模、趋势、行业分析报告：按技术、按治疗领域、按地区和细分趋势，2023-2032

Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球药物基因组学技术市场预计将达到 141 亿美元。

这份研究报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

诊断领域正在经历一场变革，以适应药物基因组测试的不断增加，而药物基因组测试通常伴随着新的生物疗法的引入。 这些测试具有双重好处，不仅可以提供具有成本效益的治疗选择，还可以增强药物开发过程。

与传统方法相比，采用这些测试的优势非常显着。 首先，这些测试可以预测疾病风险，并帮助识别更容易受到某些疾病影响的个体。 其次，这些测试有助于对患者进行分层，使医疗保健提供者能够根据每位患者的特定遗传特征制定治疗方案。 这种个人化方法可以带来更有效的治疗和更少的副作用。 最后，药物基因组学测试可以帮助监测治疗反应，以确保治疗步入正轨并允许根据需要进行调整。

药物基因组测试产品在协助医疗保健专业人员为个别患者量身定制和优化治疗方案方面发挥着重要作用。 药物基因组学和治疗诊断学领域正在为综合医学开闢新的途径。 此专门类别的分子诊断测试的快速进步将积极增强即时疾病治疗评估并改善患者护理。

然而，及时将基于药物基因组学的测试整合到药物开发过程中也存在挑战，这可能会阻碍同时批准。 旨在确定个体和人群对特定治疗反应的差异的临床试验的有效设计和实施已成为治疗诊断成功的重要组成部分。

药物基因体学技术市场报告重点

  • 由于癌症发生率不断上升，以及全球对个人化治疗、肿瘤分析和诊断产量增加的需求不断增长，预计肿瘤学将成为预测期内增长最快的领域。
  • 2022 年，PCR 细分市场占据最大市场份额。 这是因为治疗诊断学取得了重大进展，其与高效率和高通量筛选相关的优势已被最终用户所采用。
  • 2022 年，北美占据最大的市场份额。 这是由于主要参与者、发达的行业大大小小的参与者、大量的研究人员以及广泛的行业学术界网络的存在。

目录

第 1 章简介

第 2 章执行摘要

第 3 章研究方法

第 4 章全球药物基因体学技术市场洞察

  • 药物基因体学技术市场 - 产业概况
  • 药物基因体学技术市场动态
    • 促进因素和机会
      • 提高对个人化医疗保健的认识和采用
      • 技术进步
    • 抑制因素和挑战
      • 费用和退款
  • PESTLE分析
  • 药物基因体学技术的产业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第 5 章全球药物基因体学技术市场：依技术分类

  • 主要发现
  • 简介
  • PCR
  • 原位杂交
  • 免疫组织化学
  • 序列
  • 其他

第 6 章全球药物基因体学技术市场：依治疗领域划分

  • 主要发现
  • 简介
  • 肿瘤学
  • 神经系统疾病
  • 循环系统疾病
  • 免疫性疾病
  • 传染病
  • 其他

第 7 章全球药物基因体学技术市场：按地区

  • 主要发现
  • 简介
    • 2019-2032 年药物基因体学技术市场评估，地区
  • 药物基因体学技术市场 - 北美
    • 北美：药物基因体学技术市场，依治疗领域划分，2019-2032 年
    • 北美：药物基因体学技术市场，按技术，2019-2032 年
    • 药物基因体学技术市场 - 美国
    • 药物基因体学技术市场 - 加拿大
  • 药物基因体学技术市场 - 欧洲
    • 欧洲：药物基因体学技术市场，依治疗领域划分，2019-2032 年
    • 欧洲：药物基因体学技术市场，按技术，2019-2032 年
    • 药物基因体学技术市场 - 英国
    • 药物基因体学技术市场 - 法国
    • 药物基因体学技术市场 - 德国
    • 药物基因体学技术市场 - 义大利
    • 药物基因体学技术市场 - 西班牙
    • 药物基因体学技术市场 - 荷兰
    • 药物基因体学技术市场 - 俄罗斯
  • 药物基因体学技术市场 - 亚太地区
    • 亚太地区：药物基因体学技术市场，依治疗领域划分，2019-2032 年
    • 亚太地区：药物基因体学技术市场，按技术，2019-2032 年
    • 药物基因体学技术市场 - 中国
    • 药物基因体学技术市场 - 印度
    • 药物基因体学技术市场 - 马来西亚
    • 药物基因体学技术市场 - 日本
    • 药物基因组学技术市场 - 印度尼西亚
    • 药物基因体学技术市场 - 韩国
  • 药物基因体学技术市场 - 中东和非洲
    • 中东与非洲：药物基因体学技术市场，依治疗领域划分，2019-2032 年
    • 中东和非洲：药物基因组学技术市场，按技术，2019-2032 年
    • 药物基因组学技术市场 - 沙乌地阿拉伯
    • 药物基因体学技术市场 - 阿拉伯联合大公国
    • 药物基因体学技术市场 - 以色列
    • 药物基因体学技术市场 - 南非
  • 药物基因体学技术市场 - 拉丁美洲
    • 拉丁美洲：药物基因体学技术市场，依治疗领域划分，2019-2032 年
    • 拉丁美洲：药物基因体学技术市场，按技术，2019-2032 年
    • 药物基因体学技术市场 - 墨西哥
    • 药物基因体学技术市场 - 巴西
    • 药物基因体学技术市场 - 阿根廷

第 8 章竞争态势

  • 扩张与收购分析
    • 扩大
    • 收购
  • 伙伴关係/协作/协议/揭露

第 9 章公司简介

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare
  • Illumina, Inc
  • Leica Biosystems Nussloch GmBH
  • MDPI
  • Pfizer Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc
Product Code: PM3906

The global pharmacogenomics technologies market size is expected to reach USD 14.10 billion by 2032, according to a new study by Polaris Market Research.

The report "Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of diagnostics is undergoing a transformation as it adapts to the increasing availability of pharmacogenomic tests, often accompanying the introduction of new biological therapies. These tests have the dual benefit of not only providing cost-effective treatment options but also enhancing the drug development process.

The advantages associated with the adoption of these tests over traditional methods are substantial. First, they enable the prediction of disease risks, helping identify individuals who are more susceptible to certain conditions. Second, these tests aid in patient stratification, allowing healthcare providers to tailor treatments to the specific genetic characteristics of each patient. This personalized approach leads to more effective therapies and fewer adverse effects. Finally, pharmacogenomic tests are instrumental in monitoring therapeutic responses, ensuring that treatments are on track and adjustments can be made when necessary.

Pharmacogenomics testing products play a crucial role in assisting healthcare professionals in customizing and optimizing the therapeutic regimens for individual patients. The realms of pharmacogenomics and theranostics are opening new avenues for integrated medicine. The rapid advancements within this specialized category of molecular diagnostic tests are actively enhancing the assessment of real-time disease treatment, leading to improvements in patient care.

Nevertheless, there are challenges related to the timely integration of pharmacogenomic-based testing into drug development processes, which can hinder simultaneous approval. The effective design and execution of clinical trials aimed at identifying individual and population variations in response to a particular therapy have become essential factors for the success of theranostics.

Pharmacogenomics Technologies Market Report Highlights

  • The oncology segment is expected to witness the fastest growth during the forecast period, as there is growing onset of cancer, increasing need for personalized treatment, tumor profiling, rise in diagnosis rate, across the globe.
  • In 2022, PCR segment held the largest market share, as there are significant advancements in theranostics, advantages associated with its higher efficiency and high throughput screening coupled with adoption among end users.
  • In 2022, North America held the largest market share, owing to presence of key players, well developed industry big and small players, huge pool of researchers, and extensive network of industry academia.
  • The key market players include QIAGEN, GE HealthCare, Agilent Technologies, Roche, Foundation Medicine, Thermo Fisher Scientific., Leica Biosystems, and Pfizer.

Polaris Market Research has segmented the pharmacogenomics technologies market report based on technology, therapeutic area, and region:

Pharmacogenomics Technologies, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

  • PCR
  • In-situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technologies, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technologies, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacogenomics Technologies Market Insights

  • 4.1. Pharmacogenomics Technologies Market - Industry Snapshot
  • 4.2. Pharmacogenomics Technologies Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Awareness and Adoption of Personalized Healthcare
      • 4.2.1.2. Advancements in Technology
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Costs and Reimbursement
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacogenomics Technologies Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pharmacogenomics Technologies Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacogenomics Technologies, by Technology, 2019-2032 (USD Billion)
  • 5.3. PCR
    • 5.3.1. Global Pharmacogenomics Technologies Market, by PCR, by Region, 2019-2032 (USD Billion)
  • 5.4. In-situ Hybridization
    • 5.4.1. Global Pharmacogenomics Technologies Market, by In-situ Hybridization, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunohistochemistry
    • 5.5.1. Global Pharmacogenomics Technologies Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
  • 5.6. Sequencing
    • 5.6.1. Global Pharmacogenomics Technologies Market, by Sequencing, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Pharmacogenomics Technologies Market, by Therapeutic Area

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Pharmacogenomics Technologies Market, by Oncology, by Region, 2019-2032 (USD Billion)
    • 6.3.2. Lung Cancer
      • 6.3.2.1. Global Pharmacogenomics Technologies Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.3. Breast Cancer
      • 6.3.3.1. Global Pharmacogenomics Technologies Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.4. Colorectal Cancer
      • 6.3.4.1. Global Pharmacogenomics Technologies Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.5. Cervical Cancer
      • 6.3.5.1. Global Pharmacogenomics Technologies Market, by Cervical Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.6. Others
      • 6.3.6.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
  • 6.4. Neurological Disorders
    • 6.4.1. Global Pharmacogenomics Technologies Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Global Pharmacogenomics Technologies Market, by Cardiovascular Disease, by Region, 2019-2032 (USD Billion)
  • 6.6. Immunological Disorders
    • 6.6.1. Global Pharmacogenomics Technologies Market, by Immunological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.7. Infectious Diseases
    • 6.7.1. Global Pharmacogenomics Technologies Market, by Infectious Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Others
    • 6.8.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Pharmacogenomics Technologies Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Pharmacogenomics Technologies Market - North America
    • 7.3.1. North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.3.2. North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.3. Pharmacogenomics Technologies Market - U.S.
      • 7.3.3.1. U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.4. Pharmacogenomics Technologies Market - Canada
      • 7.3.4.1. Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.4. Pharmacogenomics Technologies Market - Europe
    • 7.4.1. Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.3. Pharmacogenomics Technologies Market - UK
      • 7.4.3.1. UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.4. Pharmacogenomics Technologies Market - France
      • 7.4.4.1. France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.5. Pharmacogenomics Technologies Market - Germany
      • 7.4.5.1. Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.6. Pharmacogenomics Technologies Market - Italy
      • 7.4.6.1. Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.7. Pharmacogenomics Technologies Market - Spain
      • 7.4.7.1. Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.8. Pharmacogenomics Technologies Market - Netherlands
      • 7.4.8.1. Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.9. Pharmacogenomics Technologies Market - Russia
      • 7.4.9.1. Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.5. Pharmacogenomics Technologies Market - Asia Pacific
    • 7.5.1. Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.3. Pharmacogenomics Technologies Market - China
      • 7.5.3.1. China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.4. Pharmacogenomics Technologies Market - India
      • 7.5.4.1. India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.5. Pharmacogenomics Technologies Market - Malaysia
      • 7.5.5.1. Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.6. Pharmacogenomics Technologies Market - Japan
      • 7.5.6.1. Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.7. Pharmacogenomics Technologies Market - Indonesia
      • 7.5.7.1. Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.8. Pharmacogenomics Technologies Market - South Korea
      • 7.5.8.1. South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.6. Pharmacogenomics Technologies Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.3. Pharmacogenomics Technologies Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.4. Pharmacogenomics Technologies Market - UAE
      • 7.6.4.1. UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.5. Pharmacogenomics Technologies Market - Israel
      • 7.6.5.1. Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.6. Pharmacogenomics Technologies Market - South Africa
      • 7.6.6.1. South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.7. Pharmacogenomics Technologies Market - Latin America
    • 7.7.1. Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.3. Pharmacogenomics Technologies Market - Mexico
      • 7.7.3.1. Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.4. Pharmacogenomics Technologies Market - Brazil
      • 7.7.4.1. Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.5. Pharmacogenomics Technologies Market - Argentina
      • 7.7.5.1. Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Agilent Technologies, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. F. Hoffmann-La Roche Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Foundation Medicine, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GE HealthCare
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Illumina, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Leica Biosystems Nussloch GmBH
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. MDPI
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. QIAGEN
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Thermo Fisher Scientific Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 3 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 5 North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 6 U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 7 U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 8 Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 9 Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 10 Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 11 Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 12 UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 13 UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 14 France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 15 France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 16 Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 17 Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 18 Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 19 Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 20 Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 21 Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 24 Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 25 Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 28 China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 29 China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 30 India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 31 India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 34 Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 35 Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 38 South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 39 South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 44 UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 45 UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 46 Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 47 Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 48 South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 49 South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 50 Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 51 Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 52 Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 53 Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 54 Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 55 Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 56 Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 57 Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Pharmacogenomics Technologies Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Therapeutic Area
  • Figure 7 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Technology
  • Figure 9 Global Pharmacogenomics Technologies Market, by Technology, 2022 & 2032 (USD Billion)
  • Figure 10 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Pharmacogenomics Technologies Market